Cullinan Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | — | — | — | $0.0 | $18.9 |
| Operating income | -$241.6 | -$196.9 | -$191.1 | $144.6 | -$68.0 |
| Net income | -$219.9 | -$167.4 | -$153.2 | $111.2 | -$65.6 |
| Cash Flow Statement | |||||
| Free cash flow | -$175.8 | -$145.3 | -$134.5 | -$127.8 | -$43.4 |
Shares outstanding 64.4M · Free float 50.6%
Annual filing data through FY ended December 31, 2025; float as of October 4, 2026.